8-K: Elevai Labs Secures Exclusive Global License for Novel Muscle Loss Prevention Assets

Elevai Labs has obtained an exclusive global license, excluding South Korea, to develop and commercialize two engineered probiotic assets targeting muscle loss and obesity.

Summary

• Elevai Labs has entered into a license agreement with MOA Life Plus Co., Ltd. to exclusively develop and commercialize two engineered probiotic assets, EL-22 and EL-32, for the treatment of obesity and muscle loss prevention.
• EL-22 is a clinical-stage probiotic expressing myostatin, while EL-32 is a preclinical probiotic expressing dual myostatin and activin-A antigens.
• The agreement grants Elevai global rights, excluding South Korea, and includes an upfront payment of $400,000 and 950,000 shares of Elevai common stock to MOA.
• Elevai will also pay single-digit and low double-digit royalties on net sales of the licensed products, as well as milestone payments for development and sales achievements.
• Elevai is obligated to commercialize at least one of the licensed products after human clinical trials and regulatory approvals.
• The company plans to submit an Investigational New Drug (IND) application in 2025 and initiate clinical trials in the U.S. to evaluate the probiotic approach of EL-22 and EL-32 in combination with GLP-1 receptor agonists for obesity treatment.
• Elevai has also formed two new wholly-owned subsidiaries, Elevai Skincare, Inc. and Elevai Biosciences, Inc., to separate its skincare and biopharmaceutical businesses.

Sentiment

Score: 8

Explanation: The document is positive, highlighting a strategic licensing agreement, promising product candidates, and a clear plan for future development and commercialization. The formation of new subsidiaries also indicates a positive outlook for the company's growth.

Positives

• The exclusive license provides Elevai with a significant opportunity to develop and commercialize novel treatments for obesity and muscle loss.
• EL-22 has already completed a Phase 1 clinical trial, indicating a degree of safety and tolerability.
• The combination of EL-22 and EL-32 with GLP-1 receptor agonists could address the unmet need of muscle loss associated with weight loss drugs.
• The formation of two new subsidiaries allows Elevai to focus on its core businesses and potentially accelerate growth.
• The market for anti-obesity drugs is projected to reach $100 billion by 2030, presenting a large potential market for Elevai's products.

Negatives

• Elevai is obligated to commercialize at least one of the licensed products, which may require significant investment and resources.
• The company is dependent on the success of its product candidates EL-22 and EL-32.
• The company has a limited operating history and has experienced historical losses.
• The company may be delayed in initiating, enrolling or completing any clinical trials.
• The company faces competition from third parties developing similar products.

Risks

• Elevai's ability to raise additional funding to complete the development and commercialization of its product candidates is a risk.
• There is a risk of delays in initiating, enrolling, or completing clinical trials.
• Competition from other companies developing similar products could impact Elevai's market share.
• Elevai's ability to obtain, maintain, and protect its intellectual property is crucial for its success.
• The company is dependent on third parties for manufacturing, clinical trials, and preclinical studies.

Future Outlook

Elevai plans to submit an IND application in 2025 and initiate clinical trials in the U.S. to evaluate the probiotic approach of EL-22 and EL-32 in combination with GLP-1 receptor agonists for obesity treatment. The company also aims to develop and license additional assets, broadening its expertise in aesthetics.

Management Comments

• Jordan R. Plews, PhD, Co-Founder and Chief Executive Officer of the Company, stated that the license agreement represents a transformational and strategic milestone for Elevai.
• Dr. Tim Sayed, Chief Medical Officer of Elevai, noted that myostatin is a clinically validated target and that Elevai has a differentiated, oral approach compared to other myostatin strategies.
• Deniel Mero, co-founder of Elevai Biosciences, stated that there is a large unmet need of under-developed biotechnology assets and that they look forward to unlocking the potential of EL-22.

Industry Context

The announcement is significant as it positions Elevai to capitalize on the growing market for anti-obesity treatments, particularly in combination with GLP-1 receptor agonists. The company is addressing the issue of muscle loss associated with weight loss drugs, which is a key concern in the industry. The company is also differentiating itself with an oral probiotic approach to myostatin modulation.

Comparison to Industry Standards

• The licensing agreement is similar to other deals in the biotech industry where companies acquire rights to develop and commercialize promising drug candidates.
• The upfront payment, equity consideration, royalties, and milestone payments are typical terms in such agreements.
• The focus on combining myostatin modulation with GLP-1 agonists is a novel approach that differentiates Elevai from other companies in the obesity treatment space.
• Companies like Viking Therapeutics and Regeneron are also exploring myostatin inhibition for muscle-related conditions, but Elevai's probiotic approach is unique.
• The projected $100 billion market for anti-obesity drugs by 2030, as cited by Goldman Sachs Research, highlights the significant potential for Elevai's products.

Management Changes

Stakeholder Impact

• Shareholders may benefit from the potential growth and revenue opportunities presented by the licensing agreement and new subsidiaries.
• Employees may experience changes in roles and responsibilities due to the restructuring.
• Customers may benefit from new and improved products developed by Elevai.
• Suppliers and creditors may see increased business opportunities with Elevai.

Next Steps

• Elevai plans to submit an IND application in 2025.
• Elevai will initiate clinical trials in the U.S. to evaluate EL-22 and EL-32 in combination with GLP-1 receptor agonists.
• Elevai will continue to develop and commercialize its skincare products through Elevai Skincare, Inc.
• Elevai Biosciences will focus on acquiring and developing additional biopharmaceutical technologies.

Key Dates

Keywords

myostatin, obesity, muscle loss, probiotic, GLP-1, clinical trial, biopharmaceutical, licensing, EL-22, EL-32